Email
Print
Telmisartan Market Overview:
The Telmisartan Market size is valued at $3380.4 million in 2022 and is expected to reach a value of $4,807.30 million by 2030 at a CAGR of 4.50% during the forecast period 2023-2030. during the forecast period 2023-2030. As of my last update in September 2021, the Telmisartan market had been experiencing steady growth due to its widespread use in treating hypertension and certain cardiovascular conditions. Telmisartan is an angiotensin II receptor blocker (ARB) that helps lower blood pressure by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict.
With a growing global prevalence of hypertension and related diseases, the demand for Telmisartan was increasing. The drug's efficacy, tolerability, and potential for combination therapy with other antihypertensive agents contributed to its popularity among healthcare professionals and patients alike.
Key market players were actively involved in research and development to improve the drug's formulation and expand its therapeutic applications. Additionally, generic versions of Telmisartan had become available, fostering competition and increasing affordability.
However, it's essential to refer to more recent sources for the latest updates on the Telmisartan market, as the industry landscape might have changed since my last update in 2021.
Market Snapshot:
Telmisartan Market - Report Coverage:
The “Telmisartan Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Telmisartan Market.
Telmisartan Market - Top Trends Technological advancements:
Continuous Manufacturing: Pharmaceutical manufacturers have been exploring continuous manufacturing techniques to improve efficiency, reduce costs, and enhance the quality of Telmisartan production. Continuous manufacturing allows for more streamlined processes and better control over product quality.
Nanotechnology Applications: Nanotechnology has been increasingly incorporated into drug delivery systems, including Telmisartan formulations. Nano-sized drug carriers can improve drug solubility, bioavailability, and target-specific delivery, enhancing the drug's therapeutic effectiveness.
Personalized Medicine: Advancements in genomics and biomarker identification have paved the way for personalized medicine. Tailoring Telmisartan treatments based on a patient's genetic profile can lead to more precise and effective therapies, optimizing patient outcomes.
Internet of Things (IoT) in Healthcare: IoT devices and sensors are being integrated into healthcare settings, allowing for remote monitoring of patients and real-time data collection. IoT-enabled devices can enhance patient compliance, track treatment progress, and provide valuable insights to healthcare providers.
Big Data and Analytics: The pharmaceutical industry is increasingly leveraging big data and advanced analytics to mine insights from vast amounts of data. This data-driven approach can help identify potential drug interactions, optimize dosages, and improve treatment outcomes.
Telmisartan Market - Company Product Analysis
GlaxoSmithKline (GSK): Transderm Scop is a prescription patch that delivers scopolamine, an anticholinergic medication, through the skin to prevent motion sickness. It works by blocking certain signals in the brain that cause nausea and vomiting. The patch is typically applied behind the ear and provides continuous relief for up to 3 days.
Prestige Brands Holdings: Dramamine is an over-the-counter medication used to prevent and treat motion sickness. It contains the active ingredient dimenhydrinate, which is an antihistamine that helps reduce symptoms like nausea, vomiting, and dizziness. Dramamine is available in various forms, including tablets, chewable tablets, and liquid.
Reliefband Technologies: Reliefband is a wearable device that uses neuromodulation technology to alleviate motion sickness symptoms. It applies gentle electrical stimulation to the median nerve on the underside of the wrist, which helps to rebalance the signals in the body that cause nausea and vomiting. Reliefband is adjustable and can be worn on either wrist.
The Seaplanet Company: The Boarding Ring is a wristband-type device designed to prevent motion sickness. It works by stimulating the P6 acupuncture point on the wrist using gentle pressure. The device is adjustable and reusable, and it aims to provide relief from symptoms such as nausea, vomiting, and dizziness.
Cinnagen Co. Ltd.: Cinnaser in is an oral medication developed by Cinnagen Co. Ltd. for the treatment of motion sickness. It contains the active ingredient cyclizine, which is an antihistamine that helps to reduce nausea and vomiting. Cinnaserin is available in tablet form and is primarily marketed in Iran.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Telmisartan Market. The top 10 companies in this industry are listed below:
- C.H.Boehringer Sohn AG & Ko. KG
- Genmark Generics inc.
- Torrent Pharmaceuticals Ltd.
- Solco Healthcare U.S
- Mylan Inc.
- Aurobindo Pharma Limited
- Yichang changjiang Pharmaceutical co., Ltd
- Wanbang BioPharmaceutical
- Nippon Boehringer Ingelheim Co., Ltd.
- Ratiopharm
Scope of Report:
Table of Contents
1. Telmisartan Market - Overview
1.1. Definitions and Scope
2. Telmisartan Market - Executive Summary
3. Telmisartan Market - Comparative Analysis
3.1. Company Benchmarking - Key Companies
3.2. Global Financial Analysis - Key Companies
3.3. Market Share Analysis - Key Companies
3.4. Patent Analysis
3.5. Pricing Analysis
4. Telmisartan Market - Start-up Companies Scenario
4.1. Key Start-up Company Analysis by
4.2. Investment
4.3. Revenue
4.4. Venture Capital and Funding Scenario
5. Telmisartan Market – Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing Business Index
5.3. Case Studies of Successful Ventures
6. Telmisartan Market - Forces
6.1. Market Drivers
6.2. Market Constraints
6.3. Market Challenges
6.4. Porter's Five Force Model
6.5. Bargaining Power of Suppliers
6.6. Bargaining Powers of Customers
6.7. Threat of New Entrants
6.8. Rivalry Among Existing Players
6.9. Threat of Substitutes
7. Telmisartan Market – Strategic Analysis
7.1. Value Chain Analysis
7.2. Opportunities Analysis
7.3. Market Life Cycle
8. Telmisartan Market – By Strength (Market Size – $Million/$Billion)
8.1. 20mg
8.1.1. Market Size and Forecast, By Region
8.1.2. Market Share Analysis, By Country
8.2. 40mg
8.2.1. Market Size and Forecast, By Region
8.2.2. Market Share Analysis, By Country
8.3. 80mg
8.3.1. Market Size and Forecast, By Region
8.3.2. Market Share Analysis, By Country
9. Telmisartan Market – By indication (Market Size – $Million/$Billion)
9.1. Hypertention
9.1.1. Market Size and Forecast, By Region
9.1.2. Market Share Analysis, By Country
9.2. Cardiac Arrest
9.2.1. Market Size and Forecast, By Region
9.2.2. Market Share Analysis, By Country
9.3. Stroke
9.3.1. Market Size and Forecast, By Region
9.3.2. Market Share Analysis, By Country
10. Telmisartan Market – By composition (Market Size – $Million/$Billion)
10.1. Singel
10.1.1. Market Size and Forecast, By Region
10.1.2. Market Share Analysis, By Country
10.2 Combinational
10.2.1. Market Size and Forecast, By Region
10.2.2. Market Share Analysis, By Country
11. Telmisartan Market – By Distribution Channel (Market Size – $Million/$Billion)
11.1. Hospitals Pharmacies
11.1.1. Market Size and Forecast, By Region
11.1.2. Market Share Analysis, By Country
11.2. Retail Pharmacies
11.1.1. Market Size and Forecast, By Region
11.1.2. Market Share Analysis, By Country
11.3. Online Pharmacies
11.3.1. Market Size and Forecast, By Region
11.3.2. Market Share Analysis, By Country
12. Telmisartan Market – by Geography (Market Size – $Million/$Billion)
12.1. North America
12.1.1. The U.S.
12.1.2. Canada
12.1.3. Mexico
12.2. Europe
12.2.1. UK
12.2.2. Germany
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7. Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. South Korea
12.3.5. Australia & New Zealand
12.3.6. Rest of Asia-Pacific
12.4. South America
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Chile
12.4.4. Colombia
12.4.5. Rest of South America
12.5. Rest of the World
12.5.1. Middle East
12.5.2. Africa
13. Telmisartan Market – Entropy
14. Telmisartan Market – Industry/Segment Competition Landscape
14.1. Market Share Analysis
14.1.1. Market Share by Product Type – Key Companies
14.1.2. Market Share by Region – Key Companies
14.1.3. Market Share by Country – Key Companies
14.2. Competition Matrix
14.3. Best Practices for Companies
15. Telmisartan Market – Key Company List by Country Premium
16. Telmisartan Market - Company Analysis
16.1. C.H.Boehringer Sohn AG & Ko. KG
16.2. Genmark Generics inc.
16.3. Torrent Pharmaceuticals Ltd.
16.4. Solco Healthcare U.S
16.5. Aurobindo Pharma Limited
16.6. Mylan Inc.
16.7. ichang changjiang Pharmaceutical co., Ltd
16.8. Wanbang BioPharmaceutical
16.9. Nippon Boehringer Ingelheim Co., Ltd.
16.10. Ratiopharm
16.12. Boehringer Ingelheim.
16.13. Zhejiang Huahai Pharmaceutical
16.14. Glenmark Pharmaceuticals
16.15. Zydus Cadila
16.16. Cipla
16.17. Lupin Pharmaceuticals
16.18. Mylan Pharmaceuticals
16.19. Teva Pharmaceuticals
16.20. Sandoz International
• "Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape
The Motion Sickness Treatment is forecast to grow at 4.50% during the forecast period 2023-2030.
Global Telmisartan Market size is estimated to reach $4,807.30 Million by 2030.
The leading players in the Telmisartan Market are Prestige C.H. Boehringer Sohn AG & Ko. KG, Genmark Generics inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S, Mylan Inc.